The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

A retrospective study shows sleep apnea can increase the risk for retinal vein occlusion in both men and women and is ...

Pharmaceutical company Apnimed says it's getting positive results from the clinical trials for an oral pill that could treat ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

This can lead to delays in diagnosis as sleep apnea in women can be mistaken for anxiety, depression and menopause. As the ...

Data suggest that OSA diagnoses were associated with an increased risk for physical and psychological problems in active-duty ...

After announcing a $20 million funding round in June, the startup has set its sights on growing its customer-facing workforce ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the ...

The sleep apnea detection feature that Apple's most recent Apple Watch models offer has expanded to several more countries in ...